Carhart-Harris et al., (2016)
The Lancet

A little background on this study: 12 patients (six men, six women age 30-64) with moderate-to-severe unipolar major depression were given two oral doses of psilocybin, 10mg and 25mg, one week apart in a supportive, clinical setting. The patients were monitored for adverse reactions during the sessions and during a remote follow-up period. The treatment was well tolerated by all of the patients, with no serious or unexpected adverse events taking place. Using the Quick Inventory of Depressive Symptoms (QIDS), the researchers were able to measure outcomes in depressive symptoms relative to baseline (second pic).

It’s worth noting that the researchers also found marked and sustained improvements in anxiety and anhedonia (the inability to feel pleasure) symptoms during the follow-up period. In what is nothing short of a breakthrough, this study provides support for the safety and efficacy of psilocybin for treatment-resistant depression and the general therapeutic potential of psilocybin.